Boric Acid (99.9% Granular) - Peru CAS: 10043-35-3
Related Insights
Plant-Based Proteins: Why Traceability Is the New Competitive Edge for Ingredient Procurement
As demand for textured soy protein and other plant-based ingredients grows, traceability has become a key requirement for regulatory compliance and supply chain confidence. Procurement teams should strengthen ingredient transparency to protect product quality and market access.
Solstice‑Element Solutions Deal: How Logistics and Supply‑Chain Docs Will Shift
The recent Solstice acquisition of Element Solutions brings sweeping changes to chemical shipping documentation, emergency response protocols,hra regulatory compliance, and procurement processes. This article breaks down the implications for logistics professionals, supply‑chain managers, and legal teams navigating the ownership transition.
CSRD and Chemical Supply Chain Due Diligence: How Ownership Transfers Affect Scope 3 Data
Supplier ownership changes can create unexpected challenges for Scope 3 emissions reporting under the Corporate Sustainability Reporting Directive. This guide explains how procurement and sustainability teams should manage supplier data continuity following ownership transfers.
TSCA Cybersecurity and Chemical Plant Reporting: The Iranian PLC Advisory's Compliance Implications
Cybersecurity is increasingly intersecting with environmental compliance and operational governance in the chemical industry. Understanding how cyber risk influences facility compliance helps procurement, sustainability and regulatory teams strengthen supplier oversight.
Hormuz Index at 90: Why Supply Chain Risk Remains Elevated Despite Convoy Operations
The recent improvement in convoy operations through the Strait of Hormuz has lowered the Hormuz Index, yet it remains alarmingly high at 90. Supply chain risk is still significant because factors beyond vessel movements—such as geopolitical tensions, port constraints, origination volatility, and cybersecurity threats—continue to loom. Chemical procurement teams must broaden their monitoring scope to stay ahead of these risks.
Pharmaceutical Supply Chain: H1 2026 Closing Risk Assessment
The first half of 2026 exposed major vulnerabilities in pharmaceutical supply chains. API concentration, shipping disruptions, and logistics risks are reshaping procurement strategies for H2 2026 and beyond.
Don't miss out on our updates! Subscribe to our newsletter now
We're committed to your privacy. Tradeasia uses the information you provide to us to contact you about our relevant content, products, and services. For more information, check out our privacy policy.